Page last updated: 2024-11-11

squalestatin 1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

squalestatin 1: structure given in first source; inhibits both mammalian and fungal squalene synthetase; from fungus Phoma sp (Coelomycetes) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

zaragozic acid A : A polyketide isolated from fungi that is a potent inhibitor of fungal and mammalian squalene synthase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6438355
CHEMBL ID280978
CHEBI ID75170
SCHEMBL ID408941
MeSH IDM0202501

Synonyms (43)

Synonym
(1s,3s,4s,5r,6r,7r)-1-((4s,5r)-4-acetoxy-5-methyl-3-methylene-6-phenyl-hexyl)-4,7-dihydroxy-6-((s)-6-methyl-4-methyl-oct-2-enoyloxy)-2,8-dioxa-bicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
(1s,3s,4s,5r,6r,7r)-1-((4s,5r)-4-acetoxy-5-methyl-3-methylene-6-phenyl-hexyl)-6-((e)-(4s,6s)-4,6-dimethyl-oct-2-enoyloxy)-4,7-dihydroxy-2,8-dioxa-bicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
bdbm50051873
7-[3,5-dimethyl-(e)-1-heptenylcarbonyloxy]-2,6-dihydroxy-5-[3-(2-methyl-1-methylcarbonyloxy-3-phenylpropyl)-3-butenyl]-4,8-dioxabicyclo[3.2.1]octane-1,2,3-tricarboxylic acid
gtpl3057
1s-((4s-acetoxy-5r-methyl-3-methylene-6-phenylhexyl)-6-(e)-4s,6s-dimethyloct-2-enoyloxy)-4,7s-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3s,4s,5r-tricarboxylic acid
LMPK00000001
(1s,3s,4s,5r,6r,7r)-1-[(4s,5r)-4-(acetyloxy)-5-benzyl-3-methylidenehexyl]-6-{[(2e,4s,6s)-4,6-dimethyloct-2-enoyl]oxy}-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
l 694599
(1s,3s,4s,5r,6r,7r)-1-[(4s,5r)-4-acetoxy-5-methyl-3-methylene-6-phenyl-hexyl]-6-[(e,4s,6s)-4,6-dimethyloct-2-enoyl]oxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
squalastatin s1
gr 105155x
squalestatin
l-erythro-l-glycero-d-altro-7-trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-c-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-[(2e,4s,6s)-4,6-dimethyl-2-octenoate], (7s)-
zaragozic acid a
142561-96-4
squalestatin 1
l-erythro-l-glycero-d-altro-7-trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-c-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-(4,6-dimethyl-2-octenoate), (5(2e,4s,6s),7s)-
squalestatin s1
l-erythro-l-glycero-d-altro-7-trideculo-7,4-furanosonic acid, 2,7-anhydro-3,4-di-c-carboxy-8,9,10,12,13-pentadeoxy-10-methylene-12-(phenylmethyl)-, 11-acetate 5-((2e,4s,6s)-4,6-dimethyl-2-octenoate), (7s)-
chebi:75170 ,
CHEMBL280978 ,
l-694599
(1s,3s,4s,5r,6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-[(e,4s,6s)-4,6-dimethyloct-2-enoyl]oxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid
zga ,
1117hvx02l ,
unii-1117hvx02l
3VJC
3VJE
SCHEMBL408941
gr-105155x
squalestatin i
zaragozic acid a [mi]
squalestatin a
144541-82-2
J-007666
(1s,3s,4s,5r,6r,7r)-1-[(4s,5r)-4-(acetyloxy)-5-methyl-3-methylidene-6-phenylhexyl]-6-{[(2e,4s,6s)-4,6-dimethyloct-2-enoyl]oxy}-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid (non-preferred name)
138682-84-5
Q8066579
DTXSID701018091
zaragozicacida
HY-116290
CS-0064870

Research Excerpts

Overview

Squalestatin 1 is a member of a novel family of fermentation products. It is isolated from a previously unknown Phoma species (Coelomycetes)

ExcerptReferenceRelevance
"Squalestatin 1 is a member of a novel family of fermentation products isolated from a previously unknown Phoma species (Coelomycetes). "( Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo.
Baxter, A; Fitzgerald, BJ; Hutson, JL; McCarthy, AD; Motteram, JM; Ross, BC; Sapra, M; Snowden, MA; Watson, NS; Williams, RJ, 1992
)
3.17

Treatment

Squalestatin 1 treatment increased CYP2B and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA content in hepatocyte cultures from male Wistar-Kyoto rats. The results were consistent with the previously demonstrated response dimorphism that has been attributed to differences in constitutiveCAR levels.

ExcerptReferenceRelevance
"Squalestatin 1 treatment of primary hepatocyte cultures from male Wistar-Kyoto rats produced a greater induction of CYP2B mRNA than occurred in cultures from female rats, consistent with the previously demonstrated response dimorphism that has been attributed to differences in constitutive androstane receptor (CAR) levels."( Squalestatin 1-inducible expression of rat CYP2B: evidence that an endogenous isoprenoid is an activator of the constitutive androstane receptor.
Kocarek, TA; Mercer-Haines, NA, 2002
)
2.48
"Squalestatin 1 treatment increased CYP2B and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA content in hepatocyte cultures with comparable potencies (ED50 = 5.0 and 18 nM, respectively), and significantly induced CYP2B (mRNA, immunoreactive protein, and pentoxyresorufin O-dealkylase activity) in the livers of treated rats, producing maximal increases at a dose of 25 mg/kg/day that were approximately 32-87% of phenobarbital-induced increases."( Regulation of rat hepatic cytochrome P450 expression by sterol biosynthesis inhibition: inhibitors of squalene synthase are potent inducers of CYP2B expression in primary cultured rat hepatocytes and rat liver.
Kocarek, TA; Kraniak, JM; Reddy, AB, 1998
)
1.02

Toxicity

ExcerptReferenceRelevance
"Oxidized low density lipoproteins (OxLDL) are toxic to cells of the arterial wall and trigger the expression of the inducible form of hsp 70 in cultured endothelial cells (EAhy-926) and smooth muscle cells (HUVSMC)."( Simvastatin modulates the heat shock response and cytotoxicity mediated by oxidized LDL in cultured human endothelial smooth muscle cells.
Catapano, AL; Jacoviello, C; Longoni, C; Pirillo, A; Radaelli, A, 1997
)
0.3
" In addition, uninfected neurons treated with squalestatin became resistant to the otherwise toxic effect of PrP peptides, a synthetic miniprion (sPrP106) or partially purified prion preparations."( Squalestatin cures prion-infected neurons and protects against prion neurotoxicity.
Bate, C; Diomede, L; Salmona, M; Williams, A, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
" Significant cholesterol lowering (up to 62%) for the C3 hydroxymethyl analogue 1b was observed only when this compound was dosed three times a day for 3 days."( The squalestatins: inhibitors of squalene synthase. Enzyme inhibitory activities and in vivo evaluation of C3-modified analogues.
Cox, B; Kirk, BE; Lester, MG; McCarthy, AD; Procopiou, PA; Sareen, M; Sharratt, PJ; Snowden, MA; Spooner, SJ; Watson, NS; Widdowson, J, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 2.5.1.21 (squalene synthase) inhibitorAn EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of squalene synthase (EC 2.5.1.21).
fungal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
tricarboxylic acidAn oxoacid containing three carboxy groups.
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
cyclic ketalA ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring.
oxabicycloalkane
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
polyketideNatural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)0.00050.00020.552110.0000AID336318
Protein farnesyltransferase subunit betaRattus norvegicus (Norway rat)IC50 (µMol)0.01200.00190.65072.9860AID73565
Squalene synthaseRattus norvegicus (Norway rat)IC50 (µMol)0.00630.00020.45434.2000AID204827; AID336318
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaRattus norvegicus (Norway rat)IC50 (µMol)0.01200.00190.54512.9860AID73565
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID336093Inhibition of bovine Ras FPTase1993Journal of natural products, Nov, Volume: 56, Issue:11
Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase.
AID507282Inhibition of squalene synthase in african green monkey COS7 cells assessed as of cholesterol level at 5 uM after 14 to 18 hrs by fluorescence correlation spectroscopy relative to control2008Nature chemical biology, Sep, Volume: 4, Issue:9
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation.
AID507270Inhibition of squalene synthase in african green monkey COS7 cells assessed as lateral diffusion of the outer leaflet-linked green fluorescent protein-GPI at 5 uM after 14 to 18 hrs by fluorescence correlation spectroscopy2008Nature chemical biology, Sep, Volume: 4, Issue:9
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation.
AID507286Inhibition of squalene synthase in human Jurkat JA16 cells assessed as lateral diffusion of the outer membrane leaflet-linked GFP-AKt PH nanodomain at 5 uM after 14 to 18 hrs by fluorescence correlation spectroscopy2008Nature chemical biology, Sep, Volume: 4, Issue:9
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation.
AID507274Inhibition of CD-28 triggered Akt phosphorylation in human Jurkat JA16 cells assessed as enzyme phosphorylation at Thr308 by immunoblotting analysis relative to control2008Nature chemical biology, Sep, Volume: 4, Issue:9
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation.
AID507273Inhibition of CD-28 triggered Ras/MAPK in mouse DWT6.11 cells by immunoblotting analysis2008Nature chemical biology, Sep, Volume: 4, Issue:9
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation.
AID507275Inhibition of CD-28 triggered Akt phosphorylation in human Jurkat JA16 cells assessed as enzyme phosphorylation at Ser473 by immunoblotting analysis relative to control2008Nature chemical biology, Sep, Volume: 4, Issue:9
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation.
AID507289Inhibition of squalene synthase in human Jurkat JA16 cells assessed as lateral diffusion of the outer membrane leaflet-linked Lck(1-12)-GFP nanodomain at 5 uM after 14 to 18 hrs by fluorescence correlation spectroscopy2008Nature chemical biology, Sep, Volume: 4, Issue:9
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation.
AID507279Inhibition of serine palmitoyltransferase in human Jurkat JA16 cells assessed as sphingomyelin level at 5 uM after 14 to 18 hrs by fluorescence correlation spectroscopy relative to control2008Nature chemical biology, Sep, Volume: 4, Issue:9
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation.
AID1631437Antiviral activity against Dengue virus 2 NGC infected in human K562 cells assessed as inhibition in live viral replication after 48 hrs by plaque assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID507276Inhibition of squalene synthase in mouse DWT6.11 cells assessed as sphingomyelin level at 5 uM after 14 to 18 hrs by fluorescence correlation spectroscopy relative to control2008Nature chemical biology, Sep, Volume: 4, Issue:9
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation.
AID204990In vitro concentration required to inhibit conversion of farnesyl pyrophosphate (FPP) to squalene by inhibiting Squalene synthase in rat liver microsomes1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors.
AID73565Inhibition of Farnesyltransferase2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Modeling of binding modes and inhibition mechanism of some natural ligands of farnesyl transferase using molecular docking.
AID507264Inhibition of squalene synthase in mouse DWT6.11 cells assessed as cholesterol level at 5 uM after 14 to 18 hrs by fluorescence correlation spectroscopy relative to control2008Nature chemical biology, Sep, Volume: 4, Issue:9
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation.
AID28700Partition coefficient (logP)2002Journal of medicinal chemistry, Mar-28, Volume: 45, Issue:7
Modeling of binding modes and inhibition mechanism of some natural ligands of farnesyl transferase using molecular docking.
AID204827In vitro inhibitory activity against Squalene synthase from rats1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
The squalestatins: inhibitors of squalene synthase. Enzyme inhibitory activities and in vivo evaluation of C3-modified analogues.
AID507268Inhibition of squalene synthase in african green monkey COS7 cells assessed as cholesterol level at 5 uM after 14 to 18 hrs by fluorescence correlation spectroscopy relative to control2008Nature chemical biology, Sep, Volume: 4, Issue:9
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation.
AID336318Inhibition of rat liver squalene synthase by liqiud scintillation counting1993Journal of natural products, Nov, Volume: 56, Issue:11
Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase.
AID507266Inhibition of squalene synthase in human Jurkat JA16 cells assessed as cholesterol level at 5 uM after 14 to 18 hrs by fluorescence correlation spectroscopy relative to control2008Nature chemical biology, Sep, Volume: 4, Issue:9
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2012The Journal of biological chemistry, May-25, Volume: 287, Issue:22
Binding modes of zaragozic acid A to human squalene synthase and staphylococcal dehydrosqualene synthase.
AID1346813Rat squalene synthase (Lanosterol biosynthesis pathway)1993Proceedings of the National Academy of Sciences of the United States of America, Jan-01, Volume: 90, Issue:1
Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase.
AID1346881Human squalene synthase (Lanosterol biosynthesis pathway)1998Archives of biochemistry and biophysics, Feb-15, Volume: 350, Issue:2
Truncation of human squalene synthase yields active, crystallizable protein.
AID1346881Human squalene synthase (Lanosterol biosynthesis pathway)1995Archives of biochemistry and biophysics, Feb-01, Volume: 316, Issue:2
Expression, purification, and characterization of the human squalene synthase: use of yeast and baculoviral systems.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (103)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's47 (45.63)18.2507
2000's26 (25.24)29.6817
2010's29 (28.16)24.3611
2020's1 (0.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.51 (24.57)
Research Supply Index4.65 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other101 (97.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]